Rubidazone vs adriamycin: an evaluation of their differential toxicity in the spleen colony assay system

David S Alberts, T. Van Daalen Wetters

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Rubidazone, the new semi synthetic benzol hydrazone hydrochloride derivative of daunorubicin, has proved on a molecular weight basis to be less toxic than adriamycin and similar to daunorubicin in cardiac toxicity studies in the hamster as well as in other in vivo and in vitro test systems. It has proven effectiveness against several animal tumors and human acute leukaemias. The authors have compared the inhibitory effect of rubidazone to that of adriamycin on P388 leukaemia and normal bone marrow colony forming units (CFU) using the spleen colony assay system in male DBA2 mice. The efficacy ratios (i.e., the ratio of the slopes of the normal bone marrow CFU to leukaemia CFU dose survival curves) in the spleen colony assay system for rubidazone and adriamycin were 7.8 and 7.5, respectively. This near identity of efficacy ratios for rubidazone and adriamycin correlated with the results of median survival time studies in the leukaemic mice. Their dose median survival time curves were almost parallel, having nearly identical slopes. Rubidazone's equal therapeutic index as compared to adriamycin in the spleen colony assay system together with its known decreased toxicity to cardiac muscle cells makes it an extremely promising new anthracycline derivative to study in comparison to adriamycin in human malignancies.

Original languageEnglish (US)
Pages (from-to)64-68
Number of pages5
JournalBritish Journal of Cancer
Volume34
Issue number1
StatePublished - 1976

Fingerprint

Doxorubicin
Spleen
Daunorubicin
Stem Cells
Survival
Leukemia
Bone Marrow
Leukemia P388
Hydrazones
Time and Motion Studies
Poisons
Anthracyclines
Benzene
Cardiac Myocytes
Cricetinae
zorubicin
Neoplasms
Molecular Weight

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rubidazone vs adriamycin : an evaluation of their differential toxicity in the spleen colony assay system. / Alberts, David S; Van Daalen Wetters, T.

In: British Journal of Cancer, Vol. 34, No. 1, 1976, p. 64-68.

Research output: Contribution to journalArticle

@article{8ccea401fdfd400abb84f95da9efcba8,
title = "Rubidazone vs adriamycin: an evaluation of their differential toxicity in the spleen colony assay system",
abstract = "Rubidazone, the new semi synthetic benzol hydrazone hydrochloride derivative of daunorubicin, has proved on a molecular weight basis to be less toxic than adriamycin and similar to daunorubicin in cardiac toxicity studies in the hamster as well as in other in vivo and in vitro test systems. It has proven effectiveness against several animal tumors and human acute leukaemias. The authors have compared the inhibitory effect of rubidazone to that of adriamycin on P388 leukaemia and normal bone marrow colony forming units (CFU) using the spleen colony assay system in male DBA2 mice. The efficacy ratios (i.e., the ratio of the slopes of the normal bone marrow CFU to leukaemia CFU dose survival curves) in the spleen colony assay system for rubidazone and adriamycin were 7.8 and 7.5, respectively. This near identity of efficacy ratios for rubidazone and adriamycin correlated with the results of median survival time studies in the leukaemic mice. Their dose median survival time curves were almost parallel, having nearly identical slopes. Rubidazone's equal therapeutic index as compared to adriamycin in the spleen colony assay system together with its known decreased toxicity to cardiac muscle cells makes it an extremely promising new anthracycline derivative to study in comparison to adriamycin in human malignancies.",
author = "Alberts, {David S} and {Van Daalen Wetters}, T.",
year = "1976",
language = "English (US)",
volume = "34",
pages = "64--68",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Rubidazone vs adriamycin

T2 - an evaluation of their differential toxicity in the spleen colony assay system

AU - Alberts, David S

AU - Van Daalen Wetters, T.

PY - 1976

Y1 - 1976

N2 - Rubidazone, the new semi synthetic benzol hydrazone hydrochloride derivative of daunorubicin, has proved on a molecular weight basis to be less toxic than adriamycin and similar to daunorubicin in cardiac toxicity studies in the hamster as well as in other in vivo and in vitro test systems. It has proven effectiveness against several animal tumors and human acute leukaemias. The authors have compared the inhibitory effect of rubidazone to that of adriamycin on P388 leukaemia and normal bone marrow colony forming units (CFU) using the spleen colony assay system in male DBA2 mice. The efficacy ratios (i.e., the ratio of the slopes of the normal bone marrow CFU to leukaemia CFU dose survival curves) in the spleen colony assay system for rubidazone and adriamycin were 7.8 and 7.5, respectively. This near identity of efficacy ratios for rubidazone and adriamycin correlated with the results of median survival time studies in the leukaemic mice. Their dose median survival time curves were almost parallel, having nearly identical slopes. Rubidazone's equal therapeutic index as compared to adriamycin in the spleen colony assay system together with its known decreased toxicity to cardiac muscle cells makes it an extremely promising new anthracycline derivative to study in comparison to adriamycin in human malignancies.

AB - Rubidazone, the new semi synthetic benzol hydrazone hydrochloride derivative of daunorubicin, has proved on a molecular weight basis to be less toxic than adriamycin and similar to daunorubicin in cardiac toxicity studies in the hamster as well as in other in vivo and in vitro test systems. It has proven effectiveness against several animal tumors and human acute leukaemias. The authors have compared the inhibitory effect of rubidazone to that of adriamycin on P388 leukaemia and normal bone marrow colony forming units (CFU) using the spleen colony assay system in male DBA2 mice. The efficacy ratios (i.e., the ratio of the slopes of the normal bone marrow CFU to leukaemia CFU dose survival curves) in the spleen colony assay system for rubidazone and adriamycin were 7.8 and 7.5, respectively. This near identity of efficacy ratios for rubidazone and adriamycin correlated with the results of median survival time studies in the leukaemic mice. Their dose median survival time curves were almost parallel, having nearly identical slopes. Rubidazone's equal therapeutic index as compared to adriamycin in the spleen colony assay system together with its known decreased toxicity to cardiac muscle cells makes it an extremely promising new anthracycline derivative to study in comparison to adriamycin in human malignancies.

UR - http://www.scopus.com/inward/record.url?scp=0017182544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017182544&partnerID=8YFLogxK

M3 - Article

C2 - 952715

AN - SCOPUS:0017182544

VL - 34

SP - 64

EP - 68

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -